Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value
$11.37−0.13 (-1.09%)
Close on Nov 13, 2026Market cap $695.13MP/E –Yield –
Janux Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Janux Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $119.92M, up 4.1% year over year. For fiscal 2025 it was $125.90M, up 84.1% from the year before. The highest annual figure on record is $125.90M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.90M | +84.1% |
| FY2024 | Dec 31, 2024 | $68.39M | +24.5% |
| FY2023 | Dec 31, 2023 | $54.92M | +2.8% |
| FY2022 | Dec 31, 2022 | $53.44M | +103.7% |
| FY2021 | Dec 31, 2021 | $26.24M | +762.8% |
| FY2020 | Dec 31, 2020 | $3.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $30.57M | -11.7% |
| Q2 FY2026 | Jun 30, 2026 | $30.99M | -10.6% |
| Q1 FY2026 | Mar 31, 2026 | $26.81M | +7.0% |
| Q4 FY2025 | Dec 31, 2025 | $31.55M | +51.6% |
| Q3 FY2025 | Sep 30, 2025 | $34.63M | +86.0% |
| Q2 FY2025 | Jun 30, 2025 | $34.66M | +132.7% |
| Q1 FY2025 | Mar 31, 2025 | $25.06M | +78.1% |
| Q4 FY2024 | Dec 31, 2024 | $20.81M | +70.0% |
| Q3 FY2024 | Sep 30, 2024 | $18.61M | +56.5% |
| Q2 FY2024 | Jun 30, 2024 | $14.90M | -0.2% |
| Q1 FY2024 | Mar 31, 2024 | $14.07M | -11.3% |
| Q4 FY2023 | Dec 31, 2023 | $12.24M | -20.7% |
| Q3 FY2023 | Sep 30, 2023 | $11.89M | -13.4% |
| Q2 FY2023 | Jun 30, 2023 | $14.92M | +5.9% |
| Q1 FY2023 | Mar 31, 2023 | $15.87M | +55.8% |
| Q4 FY2022 | Dec 31, 2022 | $15.43M | +38.2% |
| Q3 FY2022 | Sep 30, 2022 | $13.74M | +63.4% |
| Q2 FY2022 | Jun 30, 2022 | $14.09M | +197.4% |
| Q1 FY2022 | Mar 31, 2022 | $10.18M | +429.0% |
| Q4 FY2021 | Dec 31, 2021 | $11.17M | +1033.9% |
| Q3 FY2021 | Sep 30, 2021 | $8.41M | +907.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.74M | +603.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.93M | – |
| Q4 FY2020 | Dec 31, 2020 | $985.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $834.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $673.00K | – |
See a number that looks wrong?